Literature DB >> 21915633

Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.

Ausilia Sellitto1, Gennaro Galizia, Umberto De Fanis, Eva Lieto, Anna Zamboli, Michele Orditura, Ferdinando De Vita, Riccardo Giunta, Giacomo Lucivero, Ciro Romano.   

Abstract

CD4+CD25+Foxp3+ regulatory T cells (Treg) specialize in suppressing immune responses. In this study, 47 consecutive colon cancer patients were subjected to circulating Treg frequency assessment by flow cytometry before and after cancer resection. Thirty-two healthy subjects served as controls. Circulating Treg frequencies were significantly higher in colon cancer patients with respect to healthy controls. When patients were subgrouped according to Dukes stages, a linear relationship was observed between Dukes stages and Treg frequencies. In radically resected patients, Treg frequencies were shown to have significantly dropped down. Patients with advanced colon cancer were more likely to have significantly higher proportions of circulating Treg frequencies than Dukes A and B patients when compared to healthy subjects. Of note, nonradically resected patients were found to display reductions in-but not normalization of-Treg frequencies. These results suggest that cancer itself may be able to drive Treg recruitment as a strategy of immunoevasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915633     DOI: 10.1007/s10875-011-9585-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  45 in total

1.  CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.

Authors:  Riki Okita; Toshiaki Saeki; Shigemitsu Takashima; Yoshiyuki Yamaguchi; Tetsuya Toge
Journal:  Oncol Rep       Date:  2005-11       Impact factor: 3.906

Review 2.  Malignancy after renal transplantation: the role of immunosuppression.

Authors:  Inés Rama; Josep M Grinyó
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

Review 3.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

Review 4.  Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Authors:  Alexander J Muller; George C Prendergast
Journal:  Curr Cancer Drug Targets       Date:  2007-02       Impact factor: 3.428

Review 5.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

8.  Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.

Authors:  Miroslaw J Szczepanski; Marta Szajnik; Malgorzata Czystowska; Magis Mandapathil; Laura Strauss; Ann Welsh; Kenneth A Foon; Theresa L Whiteside; Michael Boyiadzis
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

Review 9.  Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Authors:  Rich-Henry Schabowsky; Shravan Madireddi; Rajesh Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Curr Opin Investig Drugs       Date:  2007-12

10.  Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.

Authors:  Khoon Lin Ling; Sarah E Pratap; Gaynor J Bates; Baljit Singh; Neil J Mortensen; Bruce D George; Bryan F Warren; Juan Piris; Giovanna Roncador; Stephen B Fox; Alison H Banham; Vincenzo Cerundolo
Journal:  Cancer Immun       Date:  2007-03-28
View more
  20 in total

1.  Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma.

Authors:  Li Li; Yinghua Li; Zhuomin Yin; Jing Zhu; Dingding Yan; Hanmei Lou
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

2.  Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.

Authors:  Ciro Romano; Ausilia Sellitto; Federico Chiurazzi; Luigia Simeone; Umberto De Fanis; Maddalena Raia; Luigi Del Vecchio; Giacomo Lucivero
Journal:  Int J Hematol       Date:  2014-11-29       Impact factor: 2.490

3.  Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.

Authors:  Thomas Decker; Gerhard Fischer; Wolfgang Bücke; Philipp Bücke; Frank Stotz; Andreas Grüneberger; Martina Gropp-Meier; Günther Wiedemann; Christine Pfeiffer; Christian Peschel; Katharina Götze
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-04       Impact factor: 4.553

4.  Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.

Authors:  Ciro Romano; Ausilia Sellitto; Umberto De Fanis; Antonella Balestrieri; Alfonso Savoia; Salvatore Abbadessa; Corrado Astarita; Giacomo Lucivero
Journal:  Clin Drug Investig       Date:  2015-03       Impact factor: 2.859

5.  General anesthesia combined with epidural anesthesia ameliorates the effect of fast-track surgery by mitigating immunosuppression and facilitating intestinal functional recovery in colon cancer patients.

Authors:  Wan-Kun Chen; Li Ren; Ye Wei; De-Xiang Zhu; Chang-Hong Miao; Jian-Min Xu
Journal:  Int J Colorectal Dis       Date:  2015-01-13       Impact factor: 2.571

6.  Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.

Authors:  Jessica M S Jutzy; Salma Khan; Malyn May Asuncion-Valenzuela; Terry-Ann M Milford; Kimberly J Payne; Nathan R Wall
Journal:  Cancer Microenviron       Date:  2012-02-10

Review 7.  FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.

Authors:  Changhua Zhuo; Ye Xu; Mingang Ying; Qingguo Li; Liyong Huang; Dawei Li; Sanjun Cai; Bin Li
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 8.  Regulatory T cells in inflammatory bowel diseases and colorectal cancer.

Authors:  Györgyi Műzes; Béla Molnár; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

9.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

Review 10.  Colorectal cancer and immunity: what we know and perspectives.

Authors:  Simon Pernot; Magali Terme; Thibault Voron; Orianne Colussi; Elie Marcheteau; Eric Tartour; Julien Taieb
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.